<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327655/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327655</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Inhibition of programmed cell death-1 in cytotoxic CD8+ T cells exacerbates pressure overload-induced cardiac injury through granzyme B</name><description>Background: The use of anti-programmed cell death 1 (PD-1) antibody increases heart failure (HF) risk in cancer patients with pre-existing cardiovascular conditions. However, the underlying mechanism remains incompletely understood. Methods: To evaluate the effects of anti-PD-1 antibody on transverse aortic constriction (TAC)-induced cardiac remodeling and HF, anti-PD-1 antibody-treated mice, T cell-, myeloid-, and CD8+ T cell-specific PD-1 knockout (KO) mice, and C-X-C motif chemokine receptor 3 (CXCR3) KO and granzyme B (GZMB) KO mice combined with flow cytometry, western blotting, immunofluorescence staining, pharmacological approaches, and bulk RNA-sequencing analyses were used. Results: Administration of anti-PD-1 antibody, T cell-, or CD8+ T cell-specific PD-1 deletion, but not myeloid-specific PD-1 KO, aggravated TAC-induced cardiomyopathy and HF in mice. Mechanistically, PD-1 blockade or deletion increased myocardial infiltration of CXCR3+ CD8+ T cells, which led to GZMB/perforin-mediated impairment of cardiomyocyte mitochondrial complex I to exacerbate TAC-induced cardiac injury and HF. Notably, TAC-enhanced chemotaxis, between cardiac fibroblasts (CF)-derived CXCL9/CXCL10 and CXCR3+ CD8+ T cells, was a driving force for recruiting CXCR3+ CD8+ T cells under the conditions of PD-1 blockade or deletion. The worsened TAC-induced cardiomyopathy caused by anti-PD-1 antibody or T cell-specific PD-1 deletion was rescued by genetic deletion or pharmacological blockade of GZMB and CXCR3. Conclusions: Anti-PD-1 antibody administration enhances myocardial infiltrated CXCR3+ CD8+ T cells under TAC condition via CXCL9/CXCL10-mediated chemotaxis. These CD8+ T cell-released GZMB impairs mitochondrial complex I and causes cardiomyocytes apoptosis in a perforin-dependent manner, exacerbating TAC-induced cardiomyopathy and HF. CXCL9/CXCL10-CXCR3+ CD8+ T cell axis may represent a promising target for combating anti-PD-1 antibody-associated cardiotoxicity.</description><dates><publication>2026/05/22</publication></dates><accession>GSE327655</accession><cross_references><GSM>GSM9662758</GSM><GSM>GSM9662759</GSM><GSM>GSM9662760</GSM><GSM>GSM9662761</GSM><GSM>GSM9662756</GSM><GSM>GSM9662757</GSM><GPL>24247</GPL><GSE>327655</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>